Ad
Friday, 2 September 2016
U.S. lawmakers question Mylan's Medicaid EpiPen rebates
(Reuters) - Two key U.S. congressional committee members on Friday called for an investigation into whether Mylan NV, under fire for raising the price of its EpiPen device, overcharged the government's low-income healthcare program for the allergy treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment